Online citations, reference lists, and bibliographies.
← Back to Search

The Use Of Botulinum Toxin In The Medical Management Of Benign Essential Blepharospasm.

K. I. Perman, H. Baylis, A. Rosenbaum, D. Kirschen
Published 1986 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Twenty-eight patients with mild or moderate cases of benign essential blepharospasm were treated with botulinum toxin Type A. Average follow-up was six months. The injection technique used on these patients is illustrated. The treatment was effective in virtually all patients treated, although transient; the mean interval of relief of spasm was approximately two and one-half months. Potential side effects include ptosis and epiphora. Botulinum toxin as an initial treatment or as an adjunct in postsurgical residual blepharospasm shows promise in this preliminary study.
This paper references



This paper is referenced by
10.1097/00004397-200204000-00011
Benign essential blepharospasm.
J. McCann (2002)
10.1016/0002-9394(88)90016-5
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
R. Gonnering (1988)
10.1016/B978-0-7506-9322-6.50028-3
CHAPTER 19 – Diseases of the Eyelids
J. D. Bartlett (1989)
10.1016/S0002-9394(14)76386-X
The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment.
B. Frueh (1988)
10.1016/S0161-6420(96)30770-7
Ocular pharmacology and toxicology.
A. Flach (1996)
10.1097/IOP.0b013e31816386e1
Pain Relief in Patients Receiving Periocular Botulinum Toxin A
Andrew R. Harrison (2008)
10.1016/S0161-6420(96)30773-2
Strabismus and the Academy.
J. Mims (1996)
10.1016/j.neurol.2020.03.022
Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach.
Y. Rayess (2020)
10.1016/S0161-6420(87)33337-8
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
J. Mauriello (1987)
10.1097/01.IOP.0000131732.78227.6D
Myotoxic Effects of the Skeletal Muscle-Specific Immunotoxin, Ricin-mAb35, on Orbicularis Oculi Muscle After Eyelid Injections in Rabbits
A. Harrison (2004)
10.3109/08820539209065092
Botulinum toxin in ophthalmology
J. Holmes (1992)
10.1212/WNL.40.9.1332
Assessment
(1990)
Quantification of muscle loss in the doxorubicin-treated orbicularis oculi of the monkey. Effect of local injection of doxorubicin into the eyelid.
L. McLoon (1991)
10.1017/S0317167100027748
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
S. Kraft (1988)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1007/BF02333996
Beneficial effect of botulinum A toxin in blepharospasm: 16 months' experience with 16 cases
S. Maurri (2006)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1002/MDS.870070212
Severe but temporary injury to rabbit orbicularis oculi muscle using dihematoporphyrin ether and laser photochemomyectomy
J. Wirtschafter (1992)
10.1001/ARCHOTOL.1988.01860240057024
Management of facial spasm with Clostridium botulinum toxin, type A (Oculinum)
A. W. Biglan (1988)
10.1016/j.parkreldis.2007.11.003
Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
D. Truong (2008)
10.1016/B978-0-12-644445-2.50026-X
CHAPTER 18 – Clostridial Toxins as Therapeutic Agents
A. B. Scott (1989)
10.1016/S0161-6420(87)33338-X
Effectiveness of botulinum toxin therapy for essential blepharospasm.
P. Engstrom (1987)
10.1016/S0025-6196(12)64977-5
Treatment of blepharospasm with botulinum toxin.
R. H. Kennedy (1989)
10.1212/WNL.51.4.1185
Sneddon's syndrome: Neuro-ophthalmologic manifestations in a possible autosomal recessive pattern
U. Rehany (1998)
10.1016/0039-6257(89)90040-4
Essential blepharospasm and related dystonias.
D. Jordan (1989)
10.1016/j.ophtha.2018.03.013
Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
J. Bilyk (2018)
10.1590/S0034-72802012000600004
Eficácia do resfriamento da pele no alívio da dor desencadeada pela injeção de toxina botulínica tipo A nas distonias faciais
P. Monteiro (2012)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1007/978-1-4614-4466-4_16
Spastic Facial Muscle Disorders
Juwan Park (2012)
10.1016/S0039-6257(97)81995-9
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
J. Dutton (1996)
10.1097/01.iio.0000167238.26526.a8
Benign Essential Blepharospasm
J. McCann (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar